Clinical Trial Update: Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

This clinical trial update indicates a Phase 2 study evaluating defactinib, avutometinib, and nivolumab for anti-PD-1 refractory LKB1-mutant advanced non-small …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Avutometinib (avutometinib)
• Defactinib (defactinib)
• nivolumab (nivolumab)

Snippet

Sponsor: Emory University | Conditions: Advanced Lung Adenocarcinoma, Refractory Lung Adenocarcinoma | Phase 2 | Status: RECRUITING